Beneficial effects of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

被引：0
|
作者：
Shimozato, Naotaka [1 ]
Namisaki, Tadashi [1 ]
Moriya, Kei [1 ]
Kitade, Mitsuteru [1 ]
Takeda, Kousuke [1 ]
Kawaratani, Hideto [1 ]
Kaji, Kosuke [1 ]
Okura, Yasushi [1 ]
Takaya, Hiroaki [1 ]
Sawada, Yasuhiko [1 ]
Nishimura, Norihisa [1 ]
Sato, Shinya [1 ]
Saikawa, Soichiro [1 ]
Seki, Kenichiro [1 ]
Furukawa, Masanori [1 ]
Nakanishi, Keisuke [1 ]
Kubo, Takuya [1 ]
Yoshiji, Hitoshi [1 ]
机构：
[1] Nara Med Univ, Kashihara, Nara, Japan
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2000
引用
收藏
页码：1059A / 1059A
页数：1
相关论文
共 32 条
  • [1] Effect of combined farnesoid X receptor agonist (INT747) and dipeptidyl peptidase-4 inhibitor (sitagliptin) on liver fibrosis
    Shimozato, N.
    Namisaki, T.
    Akahane, T.
    Moriya, K.
    Kitade, M.
    Kawaratani, H.
    Kaji, K.
    Okura, Y.
    Takaya, H.
    Sawada, Y.
    Nishimura, N.
    Sato, S.
    Saikawa, S.
    Seki, K.
    Furukawa, M.
    Kubo, T.
    Yoshiji, H.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S335 - S335
  • [2] Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis
    Shimozato, Naotaka
    Namisaki, Tadashi
    Kaji, Kosuke
    Kitade, Mitsuteru
    Okura, Yasushi
    Sato, Shinya
    Moriya, Kei
    Seki, Kenichiro
    Kawaratani, Hideto
    Takaya, Hiroaki
    Sawada, Yasuhiko
    Saikawa, Soichiro
    Nakanishi, Keisuke
    Furukawa, Masanori
    Fujinaga, Yukihisa
    Kubo, Takuya
    Asada, Kiyoshi
    Kitagawa, Koh
    Tsuji, Yuki
    Kaya, Daisuke
    Ozutsumi, Takahiro
    Akahane, Takemi
    Mitoro, Akira
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2019, 49 (10) : 1147 - 1161
  • [3] ANTIFIBROTIC EFFECTS OF COMBINED TREATMENT WITH FARNESOID X RECEPTOR AGONIST AND ANGIOTENSIN-II TYPE1 RECEPTOR BLOCKER ON HEPATIC FIBROGENESIS IN THE RAT MODEL OF NONALCOHOLIC STEATOHEPATITIS
    Namisaki, T.
    Okura, Y.
    Sato, S.
    Noguchi, R.
    Moriya, K.
    Kitade, M.
    Takeda, K.
    Nishimura, N.
    Sawada, Y.
    Seki, K.
    Kawaratani, H.
    Kaji, K.
    Yoshiji, H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S686 - S686
  • [4] Impact of the combination of Farnesoid X receptor agonist and angiotensin-II type1 receptor blocker on hepatic fibrogenesis in the rat model of nonalcoholic steatohepatitis
    Namisaki, Tadashi
    Okura, Yasushi
    Sato, Shinya
    Kitade, Mitsuteru
    Kaji, Kosuke
    Nishimura, Norihisa
    Moriya, Kei
    Takeda, Kosuke
    Seki, Kenichiro
    Shimozato, Naotaka
    Noguchi, Ryuichi
    Kawaratani, Hideto
    Sawada, Yasuhiko
    Yoshiji, Hitoshi
    HEPATOLOGY, 2016, 64 : 828A - 828A
  • [5] Effects of the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, on Colorectal Carcinogenesis in a Model of Type 2 Diabetes
    Inoue, Takuya
    Yorifuji, Naoki
    Fujiwara, Kaori
    Sakanaka, Taisuke
    Iguchi, Munetaka
    Narabayashi, Ken
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Umegaki, Eiji
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2014, 146 (05) : S654 - S655
  • [6] Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis
    Okura, Yasushi
    Namisaki, Tadashi
    Moriya, Kei
    Kitade, Mitsuteru
    Takeda, Kosuke
    Kaji, Kosuke
    Noguchi, Ryuichi
    Nishimura, Norihisa
    Seki, Kenichiro
    Kawaratani, Hideto
    Takaya, Hiroaki
    Sato, Shinya
    Sawada, Yasuhiko
    Shimozato, Naotaka
    Furukawa, Masanori
    Nakanishi, Keisuke
    Saikawa, Soichiro
    Kubo, Takuya
    Asada, Kiyoshi
    Yoshiji, Hitoshi
    HEPATOLOGY RESEARCH, 2017, 47 (12) : 1317 - 1328
  • [7] Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model o f nonalcoholic steatohepatitis
    Hu, Ying-Bin
    Liu, Xin-Yu
    Zhan, Wei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2213 - 2221
  • [8] NEPHROPATHY EVOLUTION IS PREVENTED BY THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR, SITAGLIPTIN, IN A RAT MODEL OF TYPE 2 DIABETES
    Mega, Cristina
    Reis, Flavio
    de Lemos, Edite Teixeira
    Vala, Helena
    Fernandes, Rosa
    Oliveira, Jorge
    Teixeira, Frederico
    Reis, Flavio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 160 - 160
  • [9] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
    Tadashi Namisaki
    Ryuichi Noguchi
    Kei Moriya
    Mitsuteru Kitade
    Yosuke Aihara
    Akitoshi Douhara
    Norihisa Nishimura
    Kosuke Takeda
    Yasushi Okura
    Hideto Kawaratani
    Hiroaki Takaya
    Kenichiro Seki
    Hitoshi Yoshiji
    Journal of Gastroenterology, 2016, 51 : 162 - 172
  • [10] Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis
    Namisaki, Tadashi
    Noguchi, Ryuichi
    Moriya, Kei
    Kitade, Mitsuteru
    Aihara, Yosuke
    Douhara, Akitoshi
    Nishimura, Norihisa
    Takeda, Kosuke
    Okura, Yasushi
    Kawaratani, Hideto
    Takaya, Hiroaki
    Seki, Kenichiro
    Yoshiji, Hitoshi
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (02) : 162 - 172
1234